Sustain III Calf (sulfamethazine 8.02 g) Dailymed
Prescription Animal - Bimeda, Inc.
Go PRO for all pill images
Description Section
Sustain III® Calf Bolus (sulfamethazine)
SUSTAINED RELEASED BOLUS (72 HOURS)Â AntibacterialÂ
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.Â
NOT FOR HUMAN USE
KEEP OUT OF REACH OF CHILDREN
Approved by FDA under NADA # 120-615
Indications & Usage Section
EACH BOLUS CONTAINS: Sulfamethazine (formulated in a sustained release base), 123.8 grains (8.02 grams).
Sustain III Calf Boluses (sulfamethazine) are intended for oral administration to ruminating replacement calves (calves over one (1) month old that are not on an all-milk diet).
Sustain III Calf Boluses are indicated for the treatment of the following diseases when caused by one or more of the following pathogenic organisms sensitive to sulfamethazine: Bacterial Pneumonia (Pasteurella spp.), Colibacillosis (Bacterial Scours) (E. coli) and Calf Diphtheria (Fusobacteriulm necrophorum).
Warnings Section
RESIDUE WARNING: Treated animals intended for human consumption should not be slaughtered for food for at least 12 days after the last dose. Exceeding two (2) consecutive doses may cause violative tissue residues to remain beyond the withdrawal time. Do not use in calves under one (1) month of age or calves being fed an all-milk diet. Use in these classes of calves may cause violative residues to remain beyond the withdrawal time. Do not use in female dairy cattle 20 months of age or older. Use of sulfamethazine in this class of cattle may cause milk residues.
Precautions Section
CAUTION: This drug, like all sulfonamides, may cause toxic reactions and irreparable injury unless administered with adequate and continuous supervision. Follow recommended dosages carefully. Fluid intake must be adequate at all times throughout the three-day therapy provided by the sustained release bolus. This product has not been shown to be effective for non-ruminating calves.
CONTACT INFORMATION: To report adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae
DOSAGE AND ADMINISTRATION: Sustain III Calf Boluses (sulfamethazine) are designed to be administered orally to ruminating replacement calves (See RESIDUE WARNING Statement). Sustain II Calf Boluses should be given according to the following dosage schedule.
This bolus may be divided for better approximation of the correct dose; however, care should be taken not to crush the bolus. Care should also be taken to ensure the entire dose has been swallowed by the animal. Observe animals following the administration to ensure boluses are not regurgitated. Lubricate bolus before dosing animals.
Sustain III Calf Boluses are designed to provide a therapeutic sulfamethazine level in approximately 6 hours, and persist in providing this level for 72 hours (3 days). After 72 hours, all animals should be re-examined for persistence of observable disease signs. If signs are present, consult a veterinarian. It is strongly recommended that a second dose be given to provide an additional 72 hours of therapy, particularly in those more severe cases. The above schedule should be used at each 72-hour interval.
Storage And Handling Section
Store at 20°C - 25°C (68°F - 77°F), with excursions permitted to 15°C - 30°C (59°F - 86°F).
Package Label.principal Display Panel
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
